Trinity Biotech is a commercial-stage biotechnology company specializing in the development, manufacturing, and marketing of clinical diagnostic products for both clinical laboratories and point-of-care settings. The company focuses on human diagnostics and diabetes management solutions, including wearable biosensors. Its product range is designed to detect various health conditions, such as autoimmune diseases, infectious diseases, sexually transmitted infections, diabetes, and disorders affecting the liver and intestine. Additionally, Trinity Biotech supplies raw materials to the life sciences and research sectors worldwide. The company's products are marketed under several brand names, including Recombigen, Unigold, MarBlot, Mardx, and Immublot. Geographically, Trinity Biotech operates primarily in two segments: the Americas and the Rest of World, with the majority of its revenue derived from the Americas.
Novus Diagnostics is focused on developing an innovative diagnostic device that addresses sepsis, a life-threatening condition caused by infections. The company's technology enables rapid detection and classification of pathogens directly from whole blood samples. By providing quick and automated pathogen identification in just minutes, Novus Diagnostics aims to enhance the ability of healthcare providers to treat patients efficiently and effectively, while also maintaining cost-effectiveness in the diagnostic process.
EpiCapture
Acquisition in 2024
EpiCapture focuses on enhancing cancer patient care through the development of non-invasive urine tests designed for the early detection and monitoring of aggressive cancers, particularly prostate cancer. The company's liquid biopsy tests analyze urine DNA to measure epigenetic biomarkers that signal the presence of aggressive disease. By generating a score that indicates the likelihood of prostate cancer progression, EpiCapture's tests assist medical professionals in identifying cancer at an early stage, potentially minimizing the necessity for invasive treatments. This innovative approach aims to improve patient outcomes through more accurate and less intrusive diagnostic methods.
Novus Diagnostics
Corporate Round in 2024
Novus Diagnostics is focused on developing an innovative diagnostic device that addresses sepsis, a life-threatening condition caused by infections. The company's technology enables rapid detection and classification of pathogens directly from whole blood samples. By providing quick and automated pathogen identification in just minutes, Novus Diagnostics aims to enhance the ability of healthcare providers to treat patients efficiently and effectively, while also maintaining cost-effectiveness in the diagnostic process.
Metabolomic Diagnostics
Acquisition in 2024
Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.
imaware
Convertible Note in 2023
imaware is a health technology company focused on enhancing individual well-being through accessible testing solutions. The company provides scientifically validated home-based tests that enable users to screen and monitor a variety of health conditions, including diabetes, prostate cancer, thyroid issues, and autoimmune diseases. By leveraging a patient-facing platform, imaware facilitates a digitally-native care model that encompasses logistics, laboratory analysis, telehealth support, and compliance expertise. This approach aims to deliver a seamless user experience, allowing patients, providers, employers, and brands to access reliable and convenient healthcare solutions from the comfort of their homes.
IMMCO Diagnostics
Acquisition in 2013
IMMCO Diagnostics specializes in autoimmune disease diagnostics through a combination of innovative medical devices and comprehensive laboratory testing services. The company offers a range of diagnostic products, including assays targeting various conditions such as collagen vascular disorders, gastrointestinal issues, liver diseases, vesiculo-bullous disorders, endocrine problems, neuroimmunological conditions, cardiovascular disorders, and hearing loss. Additionally, IMMCO Diagnostics provides a wide array of diagnostic services, encompassing serology, genetics, and pathology, with expertise in dermatology, endocrinology, gastroenterology, ocular pathology, oral pathology, otolaryngology, neurology, and rheumatology. Through its pioneering research and diagnostic capabilities, the company aims to deliver effective solutions for patients with autoimmune diseases.
Fiomi Diagnostics
Acquisition in 2012
Fiomi Diagnostics specializes in the development and marketing of diagnostic test kits, particularly focusing on point-of-care cardiac marker assays. The company's innovative technology employs a microstructured plastic chip, which facilitates precise fluid flow in lateral flow assays and utilizes an efficient fluorescence detection system. This approach allows for picomolar sensitivity in whole-blood in vitro diagnostic immunoassays, enabling the delivery of quantitative test results directly at the point of care.
Phoenix Biotech
Acquisition in 2011
Phoenix Biotech specializes in developing and manufacturing medical diagnostic products and technical services tailored for the automation of diagnostic systems. The company offers a range of recombinant-based enzyme-linked immunosorbent assay (ELISA) products focused on infectious diseases, including the TREP-SURE EIA, which detects treponema pallidum antibodies in human serum and plasma, and the TREP-CHEK Test Kit, designed for the confirmatory qualitative detection of treponema pallidum IgG antibodies. Additionally, Phoenix Biotech produces a syphilis total antibody test that detects both IgG and IgM antibodies, further enhancing its portfolio of diagnostic solutions.
Primus Corp
Acquisition in 2005
Primus Corp is designs, manufactures, and supplies hemoglobin variant testing, thalassemias, and newborn screening systems. It offers direct injection and automated analyzers; and dual-assay analyzers for the measurement of HbA1c, as well as in the identification and quantization of A2, F, and Hb variants. The company provides PDQ, a semi-automated equipment for the physician's office, clinics, and medium-size hospital laboratories; PDQ Plus, an automated equipment and method for clinics, medium-size and large hospitals, and reference labs; and Primus ultra2 resolution, a system for the detection of hemoglobinopathies using whole blood, manual hemolysates, or blood spot samples on filter paper.
Fitzgerald Industries International
Acquisition in 2004
Fitzgerald Industries International is a manufacturer and supplier of biological reagents located in Acton, Massachusetts. The company specializes in providing primary antibodies, secondary antibodies, recombinant and native proteins, ELISA kits, serum, and plasma. Fitzgerald Industries emphasizes personalized technical support, catering to the specific needs of researchers in various scientific fields. With a team composed of experienced scientists, the company aims to understand and address the challenges faced in laboratory settings. Their commitment to outstanding customer service and high-quality products at competitive prices contributes to their reputation and success in the industry.
MarDx Diagnostics
Acquisition in 2000
MarDx Diagnostics is engages in developing, manufacturing, and marketing diagnostic products in the United States. It offers Western Blot, which is used to test and confirm the primary diagnosis of certain infectious diseases, including lyme disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.